Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1283-1290

  Kono, Toru ^a   Hata, Taishi ^b   Morita, Satoshi ^c   Munemoto, Yoshinori ^d   Matsui, Takanori ^e   Kojima, Hiroshi ^e   Takemoto, Hiroyoshi ^f   Fukunaga, Mutsumi ^f   Nagata, Naoki ^g   Shimada, Mitsuo ^h   Sakamoto, Junichi ⁱ   Mishima, Hideyuki ^j  

^a Sapporo Higashi Tokushukai Hospital   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f SAKAI MUNICIPAL HOSPITAL   (Japan)

^g Kitakyushu General Hospital   (Japan)

^h UNIVERSITY OF TOKUSHIMA   (Japan)

ⁱ Tokai Central Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^j AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Colorectal cancer; Double blind randomized trial; Goshajinkigan; Oxaliplatin; Peripheral neuropathy

Indexed keywords

CHEMICALS AND DRUGS; FLUOROURACIL; FOLINIC ACID; GOSHAJINKIGAN; OXALIPLATIN; PLACEBO; TJ 107; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; ILEUS; INCIDENCE; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OXALIPLATIN INDUCED PERIPHERAL NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890390387     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2306-7     Document Type: Article

References (29)

1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Multicenter international study of oxaliplatin/5-fluorouracil/ leucovorin in the adjuvant treatment of colon cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
2. Lucchetta M, Lonardi S, Bergamo F, Alberti P, Velasco R, Argyriou AA, Briani C, Bruna J, Cazzaniga M, Cortinovis D, Cavaletti G, Kalofonos HP (2012) Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemo Pharm 70:899-902
3. Cersosimo RJ (2005) Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39:128-135
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
5. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51-60
6. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205-2211
7. Leonard GR, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thoomas RR, Grem JL (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116-126
8. Kaley TJ, Deangelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145:3-14
9. Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12:1151-1161
10. Wu Z, Ouyang J, He Z, Zhang S (2012) Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis. Eur J Cancer 48:1791-1798
11. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479-494
12. Kono T, Kanematsu T, Kitajima M (2009) Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery 146:837-840
13. Nagaki Y, Hayasaka S, Hayasaka Y, Kadoi C, Sekiya N, Terasawa K, Sakakibara I (2003) Effects of goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus. Am J Chin Med 31:103-109
14. Tawata M, Kurihara A, Nitta K, Iwase E, Gan N, Onaya T (1994) The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy. Diabetes Res Clin Pract 26:121-128
15. Uno T, Ohsawa I, Tokudome M, Sato Y (2005) Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes. Diabetes Res Clin Pract 69:129-135
16. Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T, Kamiya K (2009) Efficacy of Goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med. doi: 10.1093/ecam/nep200
17. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T, Kono T (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16:322-327
18. Kono T, Mishima H, Shimada M, Morita S, Sakamoto J (2009) GONE Investigators: preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study). Jpn J Clin Oncol 39:847-849
19. Haller DG (2000) Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park) 12(Suppl 11):15-20
20. Omiya Y, Goto K, Suzuki Y, Ishige A, Komatsu Y (1999) Analgesia-producing mechanism of processed Aconiti tuber: role of dynorphin, an endogenous kappa-opioid ligand, in the rodent spinal cord. Jpn J Pharmacol 79:295-301
21. Gotoh A, Goto K, Sengoku A, Shirakawa T, Akao Y, Fujisawa M, Okada H, Arakawa S, Kamidono S (2004) Inhibition mechanism of Gosha-jinki-gan on the micturition reflex in rats. J Pharm Sci 96:115-123
22. Imamura T, Ishizuka O, Aizawa N, Zhong C, Ogawa T, Nakayama T, Tanabe T, Nishizawa O (2008) Gosha-jinki-gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder. Neurourol Urodyn 27:832-837
23. Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9:463-472
24. Hu X, Sato J, Oshida Y, Xu M, Bajotto G, Sato Y (2003) Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 59:103-111
25. Ushio S, Egashira N, Sada H, Kawashiri T, Shirahama M, Masuguchi K, Oishi R (2012) Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer 48:1407-1413
26. Tai T, Akita Y, Kinoshita K, Koyama K, Takahashi K, Watanabe K (1995) Anti-emetic principles of Poria cocos. Planta Med 61:527-530
27. Lee JH, Lee YJ, Kang SW, Kim Y, Shin M, Hong M, Seo EK, Kim SH, Nah SY, Bae H (2010) Effects of protostane-type triterpenoids on the 5-HT3A receptor-mediated ion current in Xenopus oocytes. Brain Res 1331:20-27
28. Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657-666
29. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200-205